Jenburkt Pharmaceuticals Profit & Loss Annual

BSE: 524731 | NSE: - | ISIN: INE354A01013 | Sector: Biotechnology & Drugs

1,234.90 +72.55 (6.24%)Updated : 25 Nov 2024

Interim Data

Annual Data

Fiscal Period	2024	2023	2022	2021
Period End Date	Mar 24	Mar 23	Mar 22	Mar 21
Revenue	141.97	136.75	123.98	109.29
Total Revenue	141.97	136.75	123.98	109.29
Costof Revenue Total	30.41	34.57	32.68	30.94
Gross Profit	111.56	102.18	91.30	78.35
Selling/ General/ Admin Expenses Total	42.49	70.59	62.97	57.53
Depreciation/ Amortization	2.34	2.26	1.90	2.04
Other Operating Expenses Total	35.95	-	0.00	0.00
Total Operating Expense	111.19	108.64	98.62	91.49
Operating Income	30.78	28.11	25.36	17.81
Interest Inc( Exp) Net- Non- Op Total	-2.71	45.25	43.01	38.69
Other Net	4.67	0.23	0.03	-0.04
Net Income Before Taxes	35.18	32.86	29.87	21.64
Provisionfor Income Taxes	9.20	8.26	7.57	5.14
Net Income After Taxes	25.98	24.61	22.30	16.50
Net Income Before Extra Items	25.98	24.61	22.30	16.50
Net Income	25.98	24.61	22.30	16.50
Income Availableto Com Excl Extra Ord	25.98	24.61	22.30	16.50
Income Availableto Com Incl Extra Ord	25.98	24.61	22.30	16.50
Diluted Net Income	25.98	24.61	22.30	16.50
Diluted Weighted Average Shares	0.44	0.44	0.46	0.46
Diluted EPS Excluding Extra Ord Items	58.86	55.76	48.58	35.96
DPS- Common Stock Primary Issue	15.30	14.40	12.00	10.20
Diluted Normalized EPS	58.86	55.75	48.28	35.95
Research Development	-	12.26	10.81	9.85
Gain( Loss)on Saleof Assets	-	0.04	1.86	0.02